March 2013 | OncologyLive

Embracing a Challenge: Breast Cancer Expert Pushes Forward After Much Success

April 12, 2013

An interview with José Baselga, MD, PhD, who helped to develop new drugs and combination therapies for the treatment of breast cancer, including the early targeted therapy trastuzumab and the more recent pertuzumab.

Numerous Drug Classes Studied for Use in Follicular Lymphoma

April 09, 2013

Follicular lymphoma is characterized by repeated treatment responses and then relapses, and until more effective frontline therapies become available, researchers will need to generate a growing list of drug choices to keep pace with patients' needs.

Baselga Recaps Research Into Three Breast Cancer Pathways

April 09, 2013

José Baselga, MD, PhD, explores the dual inhibition of cell-signaling pathways in breast cancer on several fronts, including new therapies for patients with the HER2-positive subtype and novel ways to target mTOR and the PI3K/Akt/mTOR pathway.

Interferon Therapy: A Growing Family Feeds New Interest in an Older Treatment

April 01, 2013

Interferons have evolved from a "cure-all" for cancer, as they were initially touted, to a more tempered yet equally vital role in treating a number of different disease states, including many different types of cancer.

Veteran Researcher Sees Many Gaps in Knowledge About IFNs

April 01, 2013

For more than 20 years, Ahmed Lasfar, PhD, has been exploring the cell-signaling activity of interferons and he has been involved in the characterization of a new type of interferon, IFNλ, and its antitumor activity.

AGS-003 Vaccine Achieves Survival Benefits in mRCC

March 26, 2013

AGS-003, a personalized dendritic cell immunotherapy, demonstrated prolonged survival benefits in patients with metastatic renal cell carcinoma, with one-third of those who took the drug during a phase II trial still alive after nearly four years.